Jun 08, 2022 7:00am EDT The UK Medicines and Healthcare products Regulatory Agency (MHRA), Australian Therapeutic Goods Administration (TGA) and Health Canada approve KIMMTRAK® (tebentafusp) for the treatment of unresectable or metastatic uveal melanoma
Jun 06, 2022 7:00am EDT Immunocore presents new data on KIMMTRAK (tebentafusp-tebn) in metastatic cutaneous (mCM) and uveal melanoma (mUM) at the 2022 American Society of Clinical Oncology (ASCO) Annual Meeting
Jun 03, 2022 7:00am EDT Immunocore announces clinical trial collaboration with Sanofi to evaluate Sanofi’s product candidate SAR444245, non-alpha IL-2, in combination with KIMMTRAK® in patients with metastatic cutaneous melanoma
May 26, 2022 6:00pm EDT Immunocore announces upcoming presentations at the 2022 American Society of Clinical Oncology (ASCO) Annual Meeting
May 11, 2022 7:00am EDT Immunocore Reports First Quarter 2022 Financial Results and Provides Business Update
Apr 04, 2022 7:00am EDT European Commission Approves KIMMTRAK® (tebentafusp) for the treatment of unresectable or metastatic uveal melanoma
Mar 03, 2022 7:00am EST Immunocore Reports Full Year 2021 Financial Results and Provides Business Update